IO BIOTECH, INC.

$10.13 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About IO BIOTECH, INC.

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Stock Analysis

last close $10.9
1-mo return -
3-mo return -
avg daily vol. 270.45T
52-week high 17.88
52-week low 6.75
market cap. $280M
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. -
inst own. 81.3%
baraka

Subscribe now for daily local and international financial news

Subscribe